Literature DB >> 29467304

Association between implementation of a code stroke system and poststroke epilepsy.

Ziyi Chen1, Leonid Churilov1, Ziyuan Chen1, Jillian Naylor1, Miriam Koome1, Bernard Yan2, Patrick Kwan2.   

Abstract

OBJECTIVE: We aimed to investigate the effect of a code stroke system on the development of poststroke epilepsy.
METHODS: We retrospectively analyzed consecutive patients treated with IV thrombolysis under or outside the code stroke system between 2003 and 2012. Patients were followed up for at least 2 years or until death. Factors with p < 0.1 in univariate comparisons were selected for multivariable logistic and Cox regression.
RESULTS: A total of 409 patients met the eligibility criteria. Their median age at stroke onset was 75 years (interquartile range 64-83 years); 220 (53.8%) were male. The median follow-up duration was 1,074 days (interquartile range 119-1,671 days). Thirty-two patients (7.8%) had poststroke seizures during follow-up, comprising 7 (1.7%) with acute symptomatic seizures and 25 (6.1%) with late-onset seizures. Twenty-six patients (6.4%) fulfilled the definition of poststroke epilepsy. Three hundred eighteen patients (77.8%) were treated with the code stroke system while 91 (22.2%) were not. After adjustment for age and stroke etiology, use of the code stroke system was associated with decreased odds of poststroke epilepsy (odds ratio = 0.36, 95% confidence interval 0.14-0.87, p = 0.024). Cox regression showed lower adjusted hazard rates for poststroke epilepsy within 5 years for patients managed under the code stroke system (hazard ratio = 0.60, 95% confidence interval 0.47-0.79, p < 0.001).
CONCLUSION: The code stroke system was associated with reduced odds and instantaneous risk of poststroke epilepsy. Further studies are required to identify the contribution of the individual components and mechanisms against epileptogenesis after stroke. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for people with acute ischemic stroke, implementation of a code stroke system reduces the risk of poststroke epilepsy.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29467304     DOI: 10.1212/WNL.0000000000005212

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  Role of cerebral glutamate in post-stroke epileptogenesis.

Authors:  John-Paul Nicolo; Terence J O'Brien; Patrick Kwan
Journal:  Neuroimage Clin       Date:  2019-11-05       Impact factor: 4.881

2.  Risk Factors for Epilepsy After Thrombolysis for Ischemic Stroke: A Cohort Study.

Authors:  Rosane Brondani; Andrea Garcia de Almeida; Pedro Abrahim Cherubini; Thaís Leite Secchi; Marina Amaral de Oliveira; Sheila Cristina Ouriques Martins; Marino Muxfeldt Bianchin
Journal:  Front Neurol       Date:  2020-01-23       Impact factor: 4.003

3.  Asymmetric distribution of enlarged perivascular spaces in centrum semiovale may be associated with epilepsy after acute ischemic stroke.

Authors:  Nian Yu; Benjamin Sinclair; Lina Maria Garcia Posada; Zhibin Chen; Qing Di; Xingjian Lin; Scott Kolbe; Gernot Hlauschek; Patrick Kwan; Meng Law
Journal:  CNS Neurosci Ther       Date:  2022-01-03       Impact factor: 5.243

4.  Seizures after Ischemic Stroke: A Matched Multicenter Study.

Authors:  Carolina Ferreira-Atuesta; Nico Döhler; Barbara Erdélyi-Canavese; Ansgar Felbecker; Philip Siebel; Natalie Scherrer; Giulio Bicciato; Juliane Schweizer; Lucia Sinka; Lukas L Imbach; Mira Katan; Laura Abraira; Estevo Santamarina; José Álvarez-Sabín; Michael Winklehner; Tim J von Oertzen; Judith N Wagner; Gian Luigi Gigli; Anna Serafini; Francesco Janes; Giovanni Merlino; Mariarosaria Valente; Giorgia Gregoraci; Julian Conrad; Stefan Evers; Piergiorgio Lochner; Frauke Roell; Francesco Brigo; Carla Bentes; Ana Rita Peralta; Teresa Pinho E Melo; Mark R Keezer; John S Duncan; Josemir W Sander; Barbara Tettenborn; Matthias J Koepp; Marian Galovic
Journal:  Ann Neurol       Date:  2021-09-30       Impact factor: 11.274

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.